A prior autism spectrum disorder (ASD) trial, implemented by researchers from Johns Hopkins, the teaching hospital of Harvard Medical School and others in a placebo-controlled, randomized, double-blind clinical trial design, provided a daily oral administration of the phytochemical sulforaphane (derived from broccoli sprouts) for 18 weeks to 29 young men with ASD which substantially improved behaviors compared with 15 placebo recipients [1].

Behavior was quantified by parents/caregivers by the widely accepted measure of the Aberrant Behavior Checklist [2] in addition to other evaluation forms.

Sulforaphane was selected by these researchers because it up-regulates genes that protect aerobic cells against oxidative stress, inflammation, and DNA-damage, and may favorably address other cellular processes all of which are prominent and possibly mechanistic characteristics of ASD or are potentially etiologically-related factors for ASD [3-18].

Concomitantly there is known negligible toxicity associated with this product.

This prior trial obtained quite significant positive results among the 29 treated autism individuals. Specifically, those receiving sulforaphane showed substantial improvements in some ASD-related behaviors. Upon discontinuation of sulforaphane, scores rose toward pre-treatment levels.

The Therapeutics Research Institute bought essentially the same product used by the Harvard and Hopkins-affiliated researchers and obtained at least as good results.  We published these results and if you click the tab on the left side that says "Study Results from Strategy #1 and #3," you can read the actual outcomes obtained.   So what we are now planning to do is enroll as many autism families as we can [up to our available financial capabilities] and continue to track and demonstrate these same utterly remarkable outcomes.

We note that our prior Study has continued for 10 months, twice as long as the Harvard-Hopkins trial,  and the results still continue to get better and better.  There is as yet no known ceiling on how effective the strategy may be.  We advise clients to just continue along, reaping the benefits of this approach.

People beginning the Study will begin with Strategy #1 -- taking one capsule of broccoli sprouts extract [sulforaphane] each day.  The capsule may be opened up and put into any food such as applesauce or yogurt.  It has very little, if any, taste or smell.

One person each month will fill out the questionnaire [the same used by Harvard-Hopkins] to describe how the client is doing in the Study.